Article
Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society - 1 Jul 2012
Westbrook Rachel H, Lea Nicholas C, Mohamedali Azim M, Smith Alexander E, Orr David W, Roberts Lara N, Heaton Nigel D, Wendon Julia A, O'Grady John G, Heneghan Michael A, Mufti Ghulam J
Abstract excerpt
Latent myeloproliferative disorders (MPDs) can be identified by Janus kinase 2 (JAK2) mutations in patients with idiopathic Budd-Chiari syndrome (BCS). The incidence and clinical outcomes of JAK2 mutations, novel ten-eleven translocation 2 (TET2) mutations, and the 46/1 haplotype in BCS are unknown for liver transplantation (LT). We undertook molecular studies of 66 patients presenting with BCS and correlated the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.